Search | Clinical Trials Finder

Conditions: Interaction
Interventions: Oregano, Drug cocktail; Dietary Supplement · Drug
Lead sponsor: Washington State University; Other
Eligibility: 18 Years to 64 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Spokane, Washington

Conditions: Healthy
Interventions: kava (Piper methysticum); Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: Not listed
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Crohn Disease, Ulcerative Colitis
Interventions: Ustekinumab IV Infusion, Ustekinumab SC Injection, Midazolam 2 mg, Warfarin 10 mg, Vitamin K 10 mg, Omeprazole 20 mg, Dextromethorphan 30 mg, Caffeine 100 mg; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 3
States / cities: Cypress, California • Miami Springs, Florida • Durham, North Carolina

Conditions: Colitis, Ulcerative, Crohn Disease
Interventions: Caffeine, Losartan, Omeprazole, Dextromethorphan, Midazolam, Vedolizumab; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 2
States / cities: Cypress, California • Miami, Florida

Conditions: Chemotherapy-induced Nausea and Vomiting
Interventions: Rolapitant, Digoxin, Sulfasalazine, Cooperstown Cocktail; Drug
Lead sponsor: Tesaro, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Active Ulcerative Colitis
Interventions: Afimkibart, Caffeine, Warfarin, Omeprazole, Dextromethorphan, Midazolam, Vitamin K; Drug · Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 3
States / cities: Chula Vista, California • Miami, Florida

Conditions: Drug Drug Interaction (DDI)
Interventions: BMS-984923, Midazolam, Caffeine, dextromethorphan; Drug
Lead sponsor: Allyx Therapeutics; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Advanced Solid Tumors, Metastatic Melanoma
Interventions: losartan, dextromethorphan, caffeine, omeprazole, midazolam, rosuvastatin, bupropion immediate release (IR), encorafenib, binimetinib, modafinil; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 11
States / cities: Orange, California • Aurora, Colorado • Chicago, Illinois + 7 more

Conditions: Psoriasis
Interventions: Drug Cocktail, Ixekizumab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 3
States / cities: Anaheim, California • DeLand, Florida • High Point, North Carolina

Conditions: Relapsing-Remitting Multiple Sclerosis
Interventions: Midazolam, Caffeine, S-warfarin, Vitamin K, Omeprazole, Dextromethorphan, BIIB019 (Daclizumab); Drug · Other · Biological
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 7
States / cities: Centennial, Colorado • Washington D.C., District of Columbia • Lake Barrington, Illinois + 4 more

Conditions: Malignant Melanoma
Interventions: Drug cocktail, RO5185426; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 5
States / cities: Los Angeles, California • Boston, Massachusetts • Nashville, Tennessee + 1 more

Conditions: Psoriasis
Interventions: Guselkumab, Midazolam, Warfarin, Omeprazole, Dextromethorphan, Caffeine; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 8
States / cities: Anniston, Alabama • North Hollywood, California • Orlando, Florida + 5 more

Conditions: Growth Hormone Deficiency, Dwarfism
Interventions: Dextromethorphan and Caffeine; Drug
Lead sponsor: University of Louisville; Other
Eligibility: 4 Years to 14 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2008
U.S. locations: 4
States / cities: San Diego, California • Louisville, Kentucky • Kansas City, Missouri + 1 more

Conditions: Transplant Rejection
Interventions: Caffeine, Losartan, Omeprazole, Dextromethorphan, Midazolam, Belatacept; Drug · Biological
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Healthy
Interventions: Genotyping and Phenotyping using dextromethorphan and caffeine as probes; Procedure
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: 12 Months to 5 Years
Enrollment: 121 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2010
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Drug-Interactions
Interventions: ecopipam HCl ~2mg/kg/day, Cohort 1 Probe Cocktail, Cohort 2 Probe Cocktail, Cohort 3 Probe Cocktail; Drug · Combination Product
Lead sponsor: Emalex Biosciences Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Psoriasis
Interventions: Drug Cocktail, Mirikizumab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 3
States / cities: Anaheim, California • DeLand, Florida • High Point, North Carolina

Conditions: Carcinoma, Renal Cell
Interventions: GW786034 (pazopanib), Probe drugs; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 21 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Drug Interactions
Interventions: Proellex, CYP1A2 probe, CYP2C9 probe, CYP2C19 probe, CYP2D6 probe, CYP3A4 probe; Drug
Lead sponsor: Repros Therapeutics Inc.; Industry
Eligibility: 18 Years to 48 Years · Female only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: Neoplasm Metastasis
Interventions: Drug Cocktail, Abemaciclib; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 5
States / cities: Denver, Colorado • Indianapolis, Indiana • Fairway, Kansas + 2 more

Conditions: Drug-Interactions
Interventions: Inje cocktail, THC Cannabis extract, THC/CBD Cannabis Extract; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Drug Interaction
Interventions: Ecopipam, Cohort 1 Probe Substrate Cocktail, Cohort 2 Probe Substrate, Cohort 3 Probe Substrate Cocktail; Drug · Combination Product
Lead sponsor: Emalex Biosciences Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Alzheimer Disease
Interventions: Interacting drugs - Cooperstown Cocktail (midazolam, warfarin, (+ vitamin K), caffeine, omeprazole and dextromethorphan), BMS-708163, BMS-708163 + Cooperstown Cocktail; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Hamilton, New Jersey

Conditions: Food-drug Interaction
Interventions: Licorice, Alprazolam 2 MG, Caffeine 100 MG, Tolbutamide 250 mg, Dextromethorphan 30mg; Dietary Supplement · Drug
Lead sponsor: University of Illinois at Chicago; Other
Eligibility: 40 Years to 79 Years · Female only
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

Evaluating the Pharmacokinetics of Oregano and Potential Oregano-drug Interactions Using a Drug Cocktail Approach

Effects of Kava on the Body's Elimination of Caffeine and Dextromethorphan

A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis

Phase 4, Vedolizumab-4002 Post-marketing, Disease-Drug-Drug Interaction Study

An Open Label, Single Dose, Three Part Study to Assess the Effects of Rolapitant (2 mg/mL IV Solution) on the Pharmacokinetics of Digoxin; Sulfasalazine; and the Cooperstown Cocktail (Midazolam, Omeprazole, Warfarin, Caffeine, and Dextromethorphan in Healthy Subjects

An Early-Stage Study in Multiple Clinics of How Afimkibart May Affect the Body's Processing of Medicines That Rely on Cytochrome P450 Enzymes in Participants With Ulcerative Colitis

A Study Evaluating the Potential of BMS-984923 to Alter the Systemic Exposure of Three Orally Administered Probe Substrates

Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors

A Study of Ixekizumab in Participants With Plaque Psoriasis

An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis

A Pharmacokinetic Study of RO5185426 in Combination With a Drug Cocktail in Patients With Metastatic Melanoma

Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis

rhGH Therapy on Hepatic Drug Metabolism

Study to Evaluate Effect of Belatacept on Pharmacokinetics of Inje Cocktail in Healthy Volunteers

Developmental Regulation of Proteins Responsible for Transforming Drugs in the Body

Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates

A Study of Mirikizumab in Participants With Plaque Psoriasis

A Study To Test The Effect Of GW786034 (Pazopanib) On P450 Enzymes

Open-Label, Multiple-Dose, Non-Randomized Study to Assess Drug-Drug Interactions of Proellex® in Female Subjects

A Study of Abemaciclib in Participants With Cancer That is Advanced or Has Spread to Another Part(s) of the Body

Interactions Between Cannabinoids and Cytochrome P450-Metabolized Drugs

Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates for Drug Metabolism and Transport

Drug Interaction Study With a Potential Alzheimer's Disease Compound

Licorice Botanical Dietary Supplements - Metabolism and Safety in Women